참고문헌
- Davis KL, Kahn RS, Ko G, Davidson M.Dopamine in schizophrenia: a review and reconceptualization.Am J Psychiatry 1991;148: 147486.
- Lieberman JA, Kane JM, A1vir J. Provocativetests with psychostimulant drugs in schizophrenia.Psychopharmacology 1987;91:415-33.
- Laruelle M, Abi-Dargham A, Gil R, Erdos J,D'Souza CD, Zoghbi SS, et al. SPECT measurementsof dopamine transporters in schizophrenia(abstr). J Nucl Med 1996; (Suppl 37):33P.
- Laruelle M, Abi-Dargham A, van Dyck CH, GilR, De Souza CD, Erdos J, et al. Single photonemission computerized tomography imaging ofamphetamine-induced dopamine release in drugfree schizophrenic subjects. Proc Natl Acad SciUSA 1996b;93:9235-40.
- Laruelle M, Abi-Dargham A, Gil R, Kegeles L,Innis R. Increased dopamine transmission inschizophrenia: relationship to illness phases. BiolPsychiatry 1999;46:56-72.
- Reith J, Benkelfat C, Sherwin A, Yasuhara Y,Kuwabara H, Andermann F, et al. Elevated dopadecarboxylase activity in living brain of patientswith psychosis. Proc Natl Acad Sci USA1994;91:11651-4.
- Hietala J, Syvalahti E, Vuorio K, RakkolainenV, Bergman J, Haaparanta M, et al. Presynapticdopamine function in striatum of neurolepticnaive schizophrenic patients. Lancet 1995;346:lBO-I.
- Hantraye P, Brownell AL, Elmaleh D, SpealmanRD, Wullner D, Brownell GL, et al. Dopaminefiber detection by [l1C]-CFT and PET in aprimate model of parkinsonism. Neuroreport1992;3:265-8.
- Jaber M, Jones S, Giros B, Caron MG. Thedopamine transporter: A crucial componentregulating dopamine transmission. Movement Dis1997;12:629-33.
- Chinaglia G, Alvarez FJ, Probst A, Palacios JM.Mesostriatal and mesolimbic dopamine dopamineuptake binding sites are reduced in Parkinson'sdisease and progressive supranuclear palsy: Aquantitative autoradiographic study using eH]mazindol. Neuroscience 1992;49:317-27.
- Czudek C, Reynolds GP. eH]GBR 12935binding to the dopamine uptake site in postmortembrain tissue in schizophrenia. J Neural Transm 1989;77:227-30.
- Knable MB, Hyde TM, Herman MM, CarterJM, Bigelow L, Kleinman JE. Quantitativeautoradiography of dopamine Dl receptors, D2receptors, and dopamine uptake sites in postmortemstriatal specimens from schizophrenicpatients. BioI Psychiatry 1994;36: 827-35.
- Pearce RK, Seeman P, Jellinger K, TourtellotteWW. Dopamine uptake sites and dopaminereceptors in Parkinson's disease and schizophrenia.Eur Neurol 1990;30(Suppl 1): 9-14.
- Van Dyck CH, Seibyl JP, Malison RT, LaruelleM, Wallace E, Zoghbi SS, et al. Age-relateddecline in striatal dopamine transporter bindingwith iodine-123-beta- CIT SPECT. J Nucl Med1995;36:1175-81.
- Volkow ND, Fowler JS, Wang GJ, Logan J,Schlyer D, McGregor R, et al. Decreaseddopamine transporters with age in health humansubjects. Ann Neurol 1994;36:237-9.
- Lieberman JA, Sheitman BB, Kinon BJ.Neurochemical sensitization in the pathophysiologyof schizophrenia: Deficits and dysfunctionin neuronal regulation and plasticity. Neuropsychopharmacology1997;17:205-29.
- Booij J, Hemelaar JM, Speelman JD, de BruinK, Janssen AM, van Royen EA. One-day protocolfor imaging of the nigrostriatal dopaminergicpathway in Parkinson's disease by C23I]FP CITSPECT. J Nucl Med 1999;40:753-61.
- Laruelle M, Abi-Dargham A, van Dyck C, GilR, D'Souza DC, Krystal J, et al. Dopamine andserotonin transporters in patients with schizophrenia:An imaging study with C23I]-CIT. BiolPsychiatry 2000;47:371-9.
- Farde L, Nordstrom AL, Wiesel FA, Pauli S,Halldin C, Sedvall G. Positron emission tomographicanalysis of central DI and D2 dopaminereceptor occupancy in patients treated withclassical neuroleptics and clozapine. Arch Gen Psychiatry 1992;49:538- 44.
- Nordstrom AL, Farde L, Wiesel FA, ForslundK, Pauli S, Halldin C, et al. Central D2dopamine receptor occupancy in relation toantipsychotic drug effects: A double- blind PETstudy of schizophrenic patients. Bioi Psychiatry1993;33:227-35.
- Schroder J, Silvestri S, Bubeck B, Karr M,Demisch S, Scherrer S, et al. D2 dopaminereceptor up-regulation, treatment response,neurological soft signs, and extrapyramidal sideeffects in schizophrenia: A follow-up study with123H odobenzamide single photon emission computedtomography in the drug-naive state andafter neuroleptic treatment. Bioi Psychiatry1998;43:660-5.
- Lavalaye J, Linszen DH, Booij J, DingemansPMAJ, Reneman L, Habraken JBA, et al.Dopamine transporter density inn young patientswith schizophrenia assessed with e2) ]FP-CITSPECT. Schizophr Res 2001;47: 59-67.
- Burt DR, Creese I, Snyder SH. Antischizophrenicdrugs: Chronic treatment levates dopamine receptorbinding in brain. Science 1976;196:326-7.
- Clow A, Theodorou A, Jenner P, Marsden CD.Changes in rat striatal dopamine turnover andreceptor activity during on years neurolepticadministration. Eur J Pharmacology 1980;63:135-44.
- Jeon BS, Kim JM, Jeong JM, Kim KM, ChangYS, Lee DS, et al. Dopamine transporterimaging with e23I]_f! -CIT demonstrates presynapticigrostriatal dopaminergic damage inWilson's disease. J Neurol Neurosurg Psychiatry1998;65:60-4.
- Jeon BS, Jeong JM, Park SS, Kim JM, ChangYS, Song HC, et al. Dopamine transporter density measured by C23I]_f! - CIT single photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neural 1998;43:792-800.
- Damasio H, Damasio AR. Lesion analysis inneuropsychology. New York: Oxford UniversityPress; 1989. Appendix A.4.
- Joyce IN, Lexow N, Bird E, Winokur A.Organization of dopamine Dl and D2 recptors inhuman striatum: receptor autoradiographic studiesin Huntington's disease and schizophrenia.Synapse 1998;2:546-57.
- Bannon MJ, Granneman JG, Kapatos G. Thedopamine transporter: potential involvement inneuropsychiatric disorders, In: Bloom FE, KupferDJ, editors. Psychopharmacology: The FourthGeneration of Progress. New York: RavenPress; 1995. p. 179-88.
- Tatsch KR, Scherer J, Linke R, Kerner M, HahnK. Decrease of dopamine transporter binding inneuroleptic free schizophrenic patients assessedwith IPT-SPECT(abstr). J Nue! Med 1999;40Suppl:31P.
- Wong DE In vivo imaging of D2 dopaminereceptors in schizophrenia. Arch Gen Psychiatry2002;59:31-4.
- Kim SE, Lee WY, Chi DY, Choe YS, Lee KH,Choi Y, et al. SPECT imaging of dopaminetransporter with C23I]-CIT : A potential clinicaltool in Parkinson's disease. Korean J Nucl Med1996;30:19-34.
- Kim SE, Lee WY, Choe YS, Kim KM, Chi DY,Kim BT. Assessment of Parkinson's diseaseseverity with C23I]-CIT and single photon emissioncomputed tomography. J Korean NeurologicalAss 1997;15:109-20.